- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 8, 2024Tara Sutton, Emily Tremblay Shortlisted for Euromoney’s Women in Business Law Awards
-
April 24, 2024IP Leadership Executive Summit
-
April 24, 2024IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
-
April 30, 2024Navigating Generational Dynamics
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Summer 2015
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Gilead Sciences, Inc. v. Watson Labs., Inc., 15-0289 (D. Del.) | Apr. 1, 2015 | Hon. Sue L. Robinson | Letairis® (ambrisentan tablets) | RE42,462 |
| Coalition for Affordable Drugs II LLC v. Shire Inc., IPR2015-00988 (PTAB) | Apr. 1, 2015 | N/A | Lialda® (mesalamine delayed-release tablets) | 6,773,720 |
| Elan Pharma International Ltd. v. Actavis Labs. UT, Inc., 15-0291 (D. Del.) | Apr. 2, 2015 | Hon. Leonard P. Stark | Clindesse® (clindamycin phosphate vaginal cream) | 6,899,890 |
| Merck Sharp & Dohme Corp. v. Apotex Inc., 15-2384 (D.N.J.) | Apr. 2, 2015 | Hon. Peter G. Sheridan | Nasonex® (mometasone furoate nasal spray) | 6,127,353 |
| Gilead Sciences, Inc. v. Watson Labs., Inc., 15-2350 (D. Del.) | Apr. 3, 2015 | Hon. Kevin McNulty | Letairis® (ambrisentan tablets) | RE42,462 |
| Sanofi-Aventis U.S. LLC v. Accord Healthcare, Inc., 15-2520 (D.N.J.) | Apr. 6, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel Injection) | 8,927,592 |
| Sanofi-Aventis U.S. LLC v. BPI Labs, LLC, 15-2521 (D.N.J.) | Apr. 6, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel Injection) | 8,927,592 |
| Sanofi-Aventis U.S. LLC v. Dr. Reddy’s Labs., Inc., 15-2522 (D.N.J.) | Apr. 6, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel Injection) | 8,927,592 |
| Sanofi-Aventis U.S. LLC v. Glenmark Generics Inc., 15-2523 (D.N.J.) | Apr. 6, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel Injection) | 8,927,592 |
| Coalition for Affordable Drugs III LLC v. Jazz Pharms., Inc., IPR2015-01018 (PTAB) | Apr. 6, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 7,895,059 |
| Supernus Pharms., Inc. v. Actavis Inc., 15-2499 (D.N.J.) | Apr. 7, 2015 | Hon. Renee Marie Bumb | Oxtellar XR® (oxcarbazepine extended-release tablets) | 8,821,930 |
| Elan Pharma International Ltd. v. Actavis Labs. UT, Inc., 15-2528 (D.N.J.) | Apr. 8, 2015 | Hon. Jose L. Linares | Clindesse® (clindamycin phosphate vaginal cream) | 6,899,890 |
| Janssen Products, L.P. v. Cipla Ltd., 15-2549 (D.N.J.) | Apr. 9, 2015 | Hon. William H. Walls | Prezista® (darunavir tablets) |
7,700,645
8,518,987
7,126,015
7,595,408
|
| Lupin Ltd. v. Janssen Sciences Ireland UC, IPR2015-01030 (PTAB) | Apr. 9, 2015 | N/A | Prezista® (darunavir tablets) | 8,518,987 |
| Teva Pharms. USA, Inc. v. Dr. Reddy’s Labs., Ltd., 15-0306 (D. Del.) | Apr. 10, 2015 | Hon. Gregory M. Sleet | Copaxone® (glatiramer acetate for injection) | 8,969,302 |
| Janssen Products, L.P. v. Cipla Ltd., 15-0307 (D. Del.) | Apr. 10, 2015 | Hon. Sue L. Robinson | Prezista® (darunavir tablets) |
7,700,645
8,518,987
7,126,015
7,595,408
|
| U.S. Dept. of Health and Human Services v. Cipla Ltd., 15-2571 (D.N.J.) | Apr. 10, 2015 | Hon. William H. Walls | Prezista® (darunavir tablets) |
7,470,506
8,597,876
|
| Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA, LLC., 15-2631 (D.N.J.) | Apr. 13, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel Injection) | 8,927,592 |
| Mylan Pharms. Inc. v. Nissan Chemical Industries Ltd., IPR2015-01069 (PTAB) | Apr. 18, 2015 | N/A | Livalo® (pitavastatin calcium tablets) | 5,856,336 |
| Shire Development LLC v. Amneal Pharms. LLC, 15-2865 (D.N.J.) | Apr. 22, 2015 | Hon. Joseph E. Irenas | Lialda® (mesalamine delayed-release tablets) | 6,773,720 |
| Medicis Pharm. Corp. v. Taro Pharms. U.S.A., Inc., 15-2841 (D.N.J.) | Apr. 22, 2015 | Hon. Renee Marie Bumb | Zyclara® (imiquimod 3.75% cream) |
8,236,816
8,598,196
8,598,196
|
| Coalition For Affordable Drugs V LLC v. Biogen IDEC International GmbH, IPR2015-01086 (PTAB) | Apr. 22, 2015 | N/A | Tecfidera® (dimethyl fumarate delayed-release capsules) | 8,759,393 |
| Coalition For Affordable Drugs VI LLC v. Celgene Corp., IPR2015-01092 (PTAB) | Apr. 22, 2015 | N/A |
Revlimid® (lenalidomide capsules)
Pomalyst® (pomalidomide capsules)
Thalomid® (thalidomide capsules)
|
6,045,501 |
| Noven Pharms., Inc. v. Mylan Technologies Inc., 15-0328 (D. Del.) | Apr. 23, 2015 | Hon. Leonard P. Stark | Minivelle® (estradiol transdermal system) |
6,841,716
8,231,906
|
| Coalition For Affordable Drugs II LLC v. NPS Pharms., Inc., IPR2015-01093 (PTAB) | Apr. 23, 2015 | N/A | Gattex Kit® (recombinant teduglutide subcutaneous powder) | 7,056,886 |
| Coalition For Affordable Drugs VI LLC v. Celgene, IPR2015-01096 (PTAB) | Apr. 23, 2015 | N/A | Revlimid® (lenalidomide capsules) | 6,315,720 |
| Lupin Ltd. v. Senju Pharm. Co., Ltd., IPR2015-01097 (PTAB) | Apr. 23, 2015 | N/A | Prolensa® (bromfenac ophthalmic solution) | 8,754,131 |
| Lupin Ltd. v. Senju Pharm. Co., Ltd., IPR2015-01099 (PTAB) | Apr. 23, 2015 | N/A | Prolensa® (bromfenac ophthalmic solution) | 8,669,290 |
| Lupin Ltd. v. Senju Pharm. Co., Ltd., IPR2015-01100 (PTAB) | Apr. 23, 2015 | N/A | Prolensa® (bromfenac ophthalmic solution) | 8,927,606 |
| Coalition For Affordable Drugs VI LLC v. Celgene Corp., IPR2015-01102 (PTAB) | Apr. 23, 2015 | N/A | Pomalyst® (pomalidomide capsules) | 6,315,720 |
| Coalition For Affordable Drugs VI LLC v. Celgene Corp., IPR2015-01103 (PTAB) | Apr. 23, 2015 | N/A | Thalomid® (thalidomide capsules) | 6,315,720 |
| Lupin Ltd. v. Senju Pharm. Co., Ltd., IPR2015-01105 (PTAB) | Apr. 23, 2015 | N/A | Prolensa® (bromfenac ophthalmic solution) | 8,871,813 |
| Noven Pharms., Inc. v. Mylan Technologies Inc., 15-0069 (N.D.W.V.) | Apr. 24, 2015 | Hon. Irene M. Keeley | Minivelle® (estradiol transdermal system) |
6,841,716
8,231,906
|
| Apotex, Inc. v. Daiichi Sankyo, Inc., 15-3695 (N.D. Ill.) | Apr. 27, 2015 | Hon. Rebecca R. Pallmeyer | Benicar® HCT (olmesartan medoxomil / hydrochlorothiazide tablets) | 6,878,703 |
| Eli Lilly and Co. v. Lupin Ltd., 15-0673 (S.D. Ind.) | Apr. 27, 2015 | Hon. Sarah Evans Barker | Effient® (prasugrel hydrochloride tablets) |
8,404,703
8,569,325
|
| Par Pharm., Inc. v. Hyperion Therapeutics, Inc., IPR2015-01117 (PTAB) | Apr. 29, 2015 | N/A | Ravicti® (glycerol phenylbutyrate oral liquid) | 8,642,012 |
| Par Pharm., Inc. v. Hyperion Therapeutics, Inc., IPR2015-01127 (PTAB) | Apr. 29, 2015 | N/A | Ravicti® (glycerol phenylbutyrate oral liquid) | 8,404,215 |
| Horizon Pharma Ireland Ltd. v. Lupin Ltd., 15-3051 (D.N.J.) | Apr. 30, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
8,217,078
8,252,838
8,546,450
8,563,613
8,618,164
8,871,809
|
| Sanofi-Aventis U.S. LLC v. Actavis LLC, 15-3107 (D.N.J.) | May 1, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) | 8,927,592 |
| Bausch & Lomb Inc. v. Micro Labs USA, Inc., 15-3113 (D.N.J.) | May 1, 2015 | Hon. Noel L. Hillman | Bepreve® (bepotastine besilate ophthalmic solution) | 8,877,168 |
| Apotex Inc. v. Lupin Ltd., 15-0599 (E.D. Tex.) | May 1, 2015 | Hon. Robert W. Schroeder, III | Paxil CR® (paroxetine hydrochloride controlled-release tablets) | 7,229,640 |
| Coalition For Affordable Drugs V LLC v. Biogen MA Inc., IPR2015-01136 (PTAB) | May 1, 2015 | N/A | Tecfidera® (dimethyl fumarate delayed-release capsules) | 8,399,514 |
| Apotex Inc. v. Lupin Ltd., 15-0357 (D. Del.) | May 4, 2015 | Hon. Leonard P. Stark | Paxil CR® (paroxetine hydrochloride controlled-release tablets) | 7,229,640 |
| Vanda Pharms. Inc. v. Inventia Healthcare Pvt. Ltd., 15-0362 (D. Del.) | May 5, 2015 | Hon. Gregory M. Sleet | Fanapt® (iloperidone tablets) | 8,586,610 |
| Galderma Labs., L.P. v. Glenmark Generics Inc., USA, 15-1416 (N.D. Tex.) | May 6, 2015 | Hon. Barbara M. G. Lynn | Epiduo® (adapalene /benzoyl peroxide gel) |
8,071,644
8,080,537
8,129,362
8,445,543
8,809,305
|
| Jazz Pharms., Inc. v. Amneal Pharms., LLC, 15-3217 (D.N.J.) | May 7, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 8,952,062 |
| Coalition For Affordable Drugs VI LLC v. Celgene Corp., IPR2015-01169 (PTAB) | May 7, 2015 | N/A | Revlimid® (lenalidomide capsules) Pomalyst® (pomalidomide capsules) | 5,635,517 |
| Senju Pharm. Co., Ltd. v. Innopharma Licensing, Inc., 15-3240 (D.N.J.) | May 8, 2015 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) |
8,129,431
8,669,290
8,754,131
8,871,813
8,927,606
|
| Altaire Pharms., Inc. v. Paragon Biotek, Inc., PGR2015-00011 (PTAB) | May 11, 2015 | N/A | Phenylephrine Hydrochloride (phenylephrine hydrochloride ophthalmic solution) | 8,859,623 |
| Duchesnay Inc. v. Mylan Pharms. Inc., 15-0385 (D. Del.) | May 13, 2015 | Hon. Sue L. Robinson | Diclegis® (doxylamine succinate / pyridoxine hydrochloride delayed-release tablets) | 6,340,695 |
| Horizon Pharma, Inc. v. Actavis Labs. FL., Inc., 15-3322 (D.N.J.) | May 13, 2015 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
8,852,636
8,858,996
|
| Horizon Pharma, Inc. v. Dr. Reddy’s Labs. Inc., 15-3324 (D.N.J.) | May 13, 2015 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
8,852,636
8,858,996
|
| Horizon Pharma, Inc. v. Lupin Ltd., 15-3326 (D.N.J.) | May 13, 2015 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
8,852,636
8,858,996
|
| Horizon Pharma, Inc. v. Mylan Pharms. Inc., 15-3327 (D.N.J.) | May 13, 2015 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
8,852,636
8,858,996
|
| Merz Pharms., LLC v. Taro Pharms. U.S.A., Inc., 15-3720 (S.D.N.Y.) | May 14, 2015 | Hon. William H. Pauley, III | Naftin® (naftifine hydrochloride gel) | 8,778,365 |
| Horizon Pharma Ireland Ltd. v. Amneal Pharms. LLC, 15-3367 (D.N.J.) | May 15, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
8,217,078
8,252,838
8,546,450
8,563,613
8,618,164
8,871,809
|
| Takeda GmbH v. Torrent Pharma Inc., 15-3375 (D.N.J.) | May 15, 2015 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) |
8,536,206
8,604,064
8,618,142
|
| Takeda GmbH v. Micro Labs USA, Inc., 15-3376 (D.N.J.) | May 15, 2015 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) |
8,536,206
8,604,064
8,618,142
|
| Takeda GmbH v. Zydus Pharms. (USA) Inc., 15-3377 (D.N.J.) | May 15, 2015 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) |
8,536,206
8,604,064
8,618,142
|
| Takeda GmbH v. Strides Pharma, Inc., 15-3378 (D.N.J.) | May 15, 2015 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) |
8,536,206
8,604,064
8,618,142
|
| Takeda GmbH v. Apotex Corp., 15-3379 (D.N.J.) | May 15, 2015 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) |
8,536,206
8,604,064
8,618,142
|
| Takeda GmbH v. Prinston Pharm. Inc., 15-3380 (D.N.J.) | May 15, 2015 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) |
5,712,298
8,536,206
8,604,064
8,618,142
|
| Takeda GmbH v. Breckenridge Pharm. Inc., 15-3382 (D.N.J.) | May 15, 2015 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) |
5,712,298
8,536,206
8,604,064
8,618,142
|
| Takeda GmbH v. Citron Pharma LLC, 15-3383 (D.N.J.) | May 15, 2015 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) |
8,536,206
8,604,064
8,618,142
|
| Takeda GmbH v. Mylan Pharms. Inc., 15-3384 (D.N.J.) | May 15, 2015 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) |
5,712,298
8,536,206
8,604,064
8,618,142
|
| Takeda GmbH v. Hetero USA Inc., 15-3385 (D.N.J.) | May 15, 2015 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) |
8,536,206
8,618,142
8,618,142
|
| Acorda Therapeutics, Inc. v. Sun Pharm. Indus. Ltd., 15-0391 (D. Del.) | May 15, 2015 | Hon. Leonard P. Stark | Ampyra® (dalfampridine extended-release tablets) |
8,007,826
8,354,437
8,440,703
8,663,685
|
| Sanofi-Aventis U.S. LLC v. Onco Therapies Ltd., 15-3392 (D.N.J.) | May 15, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) | 8,927,592 |
| Tris Pharma, Inc. v. Actavis Labs. FL, Inc., 15-0393 (D. Del.) | May 15, 2015 | Hon. Gregory M. Sleet | Quillivant® (methylphenidate hydrochloride extended-release oral suspension) | 8,956,649 |
| Tris Pharma, Inc. v. Actavis Labs. FL, Inc., 15-3399 (D.N.J.) | May 15, 2015 | Hon. Madeline C. Arleo | Quillivant® (methylphenidate hydrochloride extended-release oral suspension) | 8,956,649 |
| Vanda Pharms. Inc. v. Inventia Healthcare Pvt. Ltd., 15-0059 (N.D.W.V.) | May 15, 2015 | Hon. Gina M. Groh | Fanapt® (iloperidone tablets) | 8,586,610 |
| Akorn, Inc. v. Senju Pharm. Co., Ltd., IPR2015-01205 (PTAB) | May 15, 2015 | N/A | Durezol® (difluprednate ophthalmic emulsion) | 6,114,319 |
| Cephalon, Inc. v. Apotex Inc., 15-0404 (D. Del.) | May 19, 2015 | Hon. Gregory M. Sleet | Treanda® (bendamustine hydrochloride for infusion) |
8,445,524
8,436,190
8,609,863
8,791,270
8,669,279
8,883,836
8,895,756
|
| Merck & CIE v. Lupin Ltd., 15-0407 (D. Del.) | May 20, 2015 | Hon. Richard G. Andrews | Safyral® (drospirenone / 17α-ethinylestradiol / levomefolate calcium tablets) | 6,441,168 |
| Eli Lilly and Co. v. HEC Pharm USA, Inc., 15-0792 (S.D. Ind.) | May 20, 2015 | Hon. Jane Magnus-Stinson | Effient® (prasugrel hydrochloride tablets) |
8,404,703
8,569,325
|
| Recro Technology LLC v. Actavis Labs. FL., Inc., 15-0413 (D. Del.) | May 21, 2015 | Hon. Gregory M. Sleet | Zohydro® (hydrocodone bitartrate extended-release capsules) |
6,228,398
6,902,742
|
| Sanofi v. Lupin Atlantis Holdings S.A., 15-0415 (D. Del.) | May 21, 2015 | Hon. Richard G. Andrews | Multaq® (dronedarone tablets) |
8,318,800
8,410,167
|
| Merck & CIE v. Lupin Ltd., 15-1472 (D. Md.) | May 21, 2015 | Hon. J. Frederick Motz | Safyral® (drospirenone / 17α-ethinylestradiol / levomefolate calcium tablets) | 6,441,168 |
| Horizon Pharma Ireland Ltd. v. IGI Labs., Inc., 15-3508 (D.N.J.) | May 21, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
8,217,078
8,252,838
8,546,450
8,563,613
8,618,164
8,871,809
|
| Coalition for Affordable Drugs VII LLC v. Pozen Inc., IPR2015-01241 (PTAB) | May 21, 2015 | N/A | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) | 6,926,907 |
| Kowa Co., Ltd. v. Lupin Ltd, 15-3935 (S.D.N.Y.) | May 21, 2015 | Hon. Paul A. Crotty | Livalo® (pitavastatin calcium tablets) | 8,557,993 |
| Kowa Co., Ltd. v. Lupin Ltd, 15-1495 (D. Md.) | May 22, 2015 | Hon. George Jarrod Hazel | Livalo® (pitavastatin calcium tablets) | 8,557,993 |
| Cipla Ltd. v. Sunovion Pharms. Inc., 15-0424 (D. Del.) | May 26, 2015 | Hon. Leonard P. Stark | Xopenex HFA® (levalbuterol tartrate) | RE43,984 |
| Janssen Pharms., Inc. v. Vintage Pharms. LLC, 15-3542 (D.N.J.) | May 26, 2015 | Hon. Stanley R. Chesler | Ortho Tri-cyclen® Lo (norgestimate / ethinyl estradiol tablets) | 6,214,815 |
| Duchesnay Inc. v. Mylan Pharms. Inc., 15-0092 (N.D.W.V.) | May 27, 2015 | Hon. Irene M. Keeley | Diclegis® (doxylamine succinate / pyridoxine hydrochloride delayed-release tablets) | 6,340,695 |
| Takeda GmbH v. Mylan Pharms. Inc., 15-0093 (N.D.W.V.) | May 27, 2015 | Hon. Irene M. Keeley | Daliresp® (roflumilast tablets) |
5,712,298
8,536,206
8,604,064
8,618,142
|
| Janssen Pharms., Inc. v. Vintage Pharms. LLC, 15-0429 (D. Del.) | May 28, 2015 | Hon. Richard G. Andrews | Ortho Tri-cyclen® Lo (norgestimate / ethinyl estradiol tablets) | 6,214,815 |
| Forest Labs., LLC v. Amneal Pharms., LLC, 15-0430 (D. Del.) | May 28, 2015 | Hon. Sue L. Robinson | Saphris® (asenapine maleate tablets) | 5,763,476 |
| Warner Chilcott Co., LLC v. Amneal Pharms. LLC, 15-3590 (D.N.J.) | May 28, 2015 | Hon. Mary L. Cooper | Minastrin® 24 Fe (ethinyl estradiol / norethindrone acetate / ferrous fumarate tablets) | 6,667,050 |
| Novartis Pharms. Corp. v. Apotex, Inc., 15-3634 (D.N.J.) | May 29, 2015 | Hon. Susan D. Wigenton | Zometa® (zoledronic acid concentrate for intravenous infusion) | 8,324,189 |
| Fresenius Kabi USA, LLC v. Fera Pharms., LLC, 15-3654 (D.N.J.) | May 29, 2015 | Hon. Claire C. Cecchi | Levothyroxine Sodium (levothyroxine sodium powder for injection) | 9,006,289 |
| Fresenius Kabi USA, LLC v. Innopharma Licensing, LLC, 15-3655 (D.N.J.) | May 29, 2015 | Hon. Claire C. Cecchi | Levothyroxine Sodium (levothyroxine sodium powder for injection) | 9,006,289 |
| Mylan Pharms., Inc. v. Janssen Pharms., Inc., 15-2990 (E.D. Pa.) | May 29, 2015 | Hon. Mark A. Kearney | Concerta® (methylphenidate hydrochloride extended-release tablets) | 8,629,179 |
| Jazz Pharms., Inc. v. Roxane Labs., Inc., 15-3684 (D.N.J.) | June 1, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 8,952,062 |
| Takeda Pharm. Co. Ltd. v. Actavis Labs. FL, Inc., 15-0451 (D. Del.) | June 3, 2015 | Hon. Richard G. Andrews | Contrave® (naltrexone hydrochloride / bupropion hydrochloride extended-release tablets) |
7,375,111
7,462,626
8,088,786
8,318,788
8,722,085
8,815,889
8,916,195
|
| Teijin Ltd. v. Macleods Pharms. Ltd., 15-0454 (D. Del.) | June 4, 2015 | Hon. Sue L. Robinson | Uloric® (febuxostat tablets) | 7,361,676 |
| Apotex Corp. v. Allergan, Inc., IPR2015-01278 (PTAB) | June 4, 2015 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,633,162 |
| Apotex Corp. v. Allergan, Inc., IPR2015-01282 (PTAB) | June 4, 2015 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,629,111 |
| Apotex Corp. v. Allergan, Inc., IPR2015-01283 (PTAB) | June 4, 2015 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,685,930 |
| Apotex Corp. v. Allergan, Inc., IPR2015-01284 (PTAB) | June 4, 2015 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,648,048 |
| Apotex Corp. v. Allergan, Inc., IPR2015-01286 (PTAB) | June 4, 2015 | N/A | Restasis® (cyclosporine ophthalmic emulsion) | 8,642,556 |
| Mylan Pharms., Inc. v. AstraZeneca AB, IPR2015-01340 (PTAB) | June 4, 2015 | N/A |
Onglyza® (saxagliptin hydrochloride tablets) Kombiglyze® XR (metformin hydrochloride /
saxagliptin hydrochloride extended-release tablets)
|
RE44,186 |
| Bayer Pharma AG v. Macleods Pharms. Ltd., 15-0464 (D. Del.) | June 5, 2015 | Hon. Gregory M. Sleet | Staxyn® (vardenafil hydrochloride tablets) | 8,613,950 |
| Mallinckrodt LLC v. Watson Labs., Inc.-Florida, 15-3800 (D.N.J.) | June 5, 2015 | Hon. Katharine S. Hayden | Xartemis® XR (acetaminophen / oxycodone hydrochloride extended-release tablets) |
8,597,681
8,658,631
8,741,885
8,980,319
8,992,975
7,976,870
8,668,929
|
| Bausch & Lomb Inc. v. Apotex Inc., 15-3879 (D.N.J.) | June 5, 2015 | Hon. Noel L. Hillman | Bepreve® (bepotastine besilate ophthalmic solution) |
8,784,789
8,877,168
|
| Coalition for Affordable Drugs VII LLC v. Pozen Inc., IPR2015-01344 (PTAB) | June 5, 2015 | N/A | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) | 8,858,996 |
| Actavis Labs. UT, Inc. v. UCB, Inc., 15-1001 (E.D. Tex.) | June 8, 2015 | Hon. Rodney Gilstrap | Neupro® (rotigotine transdermal system) | 7,921,999 |
| Fresenius Kabi USA, LLC v. Par Sterile Products, LLC, 15-3852 (D.N.J.) | June 9, 2015 | Hon. Claire C. Cecchi | Levothyroxine Sodium (levothyroxine sodium powder for injection) | 9,006,289 |
| Novartis Pharms. Corp. v. Roxane Labs., Inc., 15-0474 (D. Del.) | June 10, 2015 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) |
9,006,224
8,410,131
|
| Novartis Pharms. Corp. v. Par Pharm., Inc., 15-0475 (D. Del.) | June 10, 2015 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) | 9,006,224 |
| Reckitt Benckiser Pharms. Inc. v. Alvogen Pine Brook, Inc., 15-0477 (D. Del.) | June 10, 2015 | Hon. Richard G. Andrews | Suboxone (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) |
8,475,832
8,017,150
8,603,514
8,900,497
8,906,277
|
| Alcon Research, Ltd. v. Akorn Inc., 15-0479 (D. Del.) | June 11, 2015 | Hon. Sue L. Robinson | Travatan Z® (travoprost ophthalmic solution) |
8,268,299
8,323,630
8,388,941
|
| Par Pharm., Inc. v. Breckenridge Pharm., Inc., 15-0486 (D. Del.) | June 12, 2015 | Hon. Sue L. Robinson | Megace® ES (megestrol acetate oral suspension) | 9,040,088 |
| Meda Pharms. Inc. v. Roxane Labs., Inc., 15-0510 (D. Del.) | June 17, 2015 | Hon. Gregory M. Sleet | Astepro® (azelastine hydrochloride nasal spray) |
8,071,073
8,518,919
|
| Hetero Labs Ltd. Unit V v. Pharmacia & Upjohn Co. LLC, 15-5396 (N.D. Ill.) | June 18, 2015 | Hon. Matthew F. Kennelly | Zyvox® (linezolid tablets) |
6,514,529
6,559,305
|
| Ferring B.V. v. Actavis, Inc., 15-4222 (D.N.J.) | June 23, 2015 | Hon. Katharine S. Hayden | Lysteda® (tranexamic acid tablets) | 9,060,939 |
| Cephalon, Inc. v. Fresenius Kabi USA, LLC, 15-0536 (D. Del.) | June 24, 2015 | Hon. Leonard P. Stark | Treanda® (bendamustine hydrochloride for infusion) | 8,344,006 |
| Pharmacosmos A/S v. Luitpold Pharms., Inc., IPR2015-01490 (PTAB) | June 24, 2015 | N/A | Injectafer® (ferric carboxymaltose for injection) | 7,754,702 |
| Pharmacosmos A/S v. Luitpold Pharms., Inc., IPR2015-01495 (PTAB) | June 24, 2015 | N/A | Injectafer® (ferric carboxymaltose for injection) | 8,895,612 |
| Millennium Pharms., Inc. v. Dr. Reddy’s Labs., Ltd., 15-0539 (D. Del.) | June 25, 2015 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) |
6,713,446
6,958,319
|
| Novartis Pharms. Corp. v. Aurobindo Pharma Ltd., 15-4427 (D.N.J.) | June 25, 2015 | Hon. Susan D. Wigenton | Zometa® (zoledronic acid concentrate for intravenous infusion) | 8,324,189 |
| Reckitt Benckiser LLC v. Dr. Reddy’s Labs., Inc., 15-4524 (D.N.J.) | June 26, 2015 | Hon. Renee Marie Bumb | Mucinex® D (guaifenesin / pseudoephedrine hydrochloride extended-release tablets) |
6,372,252
6,955,821
7,838,032
|
| Jazz Pharms., Inc. v. Watson Labs., Inc., 15-4532 (D.N.J.) | June 26, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) |
8,859,619
8,952,062
|
| Salix Pharms., Inc. v. Mylan Pharms., Inc., 15-0109 (N.D.W.V.) | June 26, 2015 | Hon. Irene M. Keeley | Apriso® (mesalamine extended-release capsules) |
6,551,620
8,337,886
8,496,965
8,865,688
|
| Panacea Biotec Ltd. v. Daiichi Sankyo Co., Ltd., IPR2015-01492 (PTAB) | June 26, 2015 | N/A | Effient® (prasugrel hydrochloride tablets) | 8,569,325 |
| Panacea Biotec Ltd. v. Daiichi Sankyo Co., Ltd., IPR2015-01496 (PTAB) | June 26, 2015 | N/A | Effient® (prasugrel hydrochloride tablets) | 8,404,703 |
| Gilead Sciences, Inc. v. Sigmapharm Labs., LLC, 15-4898 (D.N.J.) | June 30, 2015 | Hon. Renee Marie Bumb | Letairis® (ambrisentan tablets) | RE42,462 |
| Horizon Pharma Ireland Ltd. v. Taro Pharms. USA, Inc., 15-5021 (D.N.J.) | June 30, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,066,913 |
| Horizon Pharma Ireland Ltd. v. IGI Pharms., Inc., 15-5022 (D.N.J.) | June 30, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,066,913 |
| Horizon Pharma Ireland Ltd. v. Amneal Pharms. LLC, 15-5024 (D.N.J.) | June 30, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,066,913 |
| Horizon Pharma Ireland Ltd. v. Actavis Labs. UT, Inc., 15-5025 (D.N.J.) | June 30, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,066,913 |
| Horizon Pharma Ireland Ltd. v. Lupin Ltd., 15-5027 (D.N.J.) | June 30, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,066,913 |
GENERICally Speaking Summer 2015
Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.